Evidence map›Paper›PMID 41919978›Full record

ArticleACS nano2026

DNA Repair Enzyme Regulation Strategy for Enhanced Pancreatic Neuroendocrine Tumor Therapy via Targeting siRNA-Lipid Nanoparticles.

Fei Wang, Yan Li, Junfeng Xu, Wei Tang, Xiaowu Xu, Xin Lou, Desheng Jing, Guixiong Fan, Yi Qin, Jie Chen and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Fei WangDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Yan LiDepartment of Cardiology, Shanghai Tenth People's Hospital, Tongji University, School of Medicine, Shanghai 200072, P. R. China.
Junfeng XuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Wei TangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Xiaowu XuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xin LouDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Desheng JingDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Guixiong FanDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Yi QinDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Jie ChenCenter for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xianjun YuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Weibo CaiDepartments of Radiology and Medical Physics, University of Wisconsin, Madison 53705, Wisconsin, United States.ORCID 0000-0003-4641-0833
Zhongmin TangDepartment of Cardiology, Shanghai Tenth People's Hospital, Tongji University, School of Medicine, Shanghai 200072, P. R. China.ORCID 0000-0002-1532-8004
Shunrong JiDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
NCI NIH HHS P30 CA014520
6 · The paper itself

Abstract

Pancreatic neuroendocrine tumors (panNETs) originate from neuroendocrine cells with high rates of metastasis, rendering many patients ineligible for surgical resection. The first-line chemotherapeutic agent Temozolomide (TMZ) for metastatic panNETs faces challenges related to resistance, primarily mediated by the DNA repair enzyme O

Indexed as

DNA Modification MethylasesDNA Repair EnzymesNanoparticlesNeuroendocrine TumorsPancreatic NeoplasmsRNA, Small InterferingTumor Suppressor ProteinsAnimalsAntineoplastic Agents, AlkylatingCell Line, TumorDNA RepairHumansLipidsLiposomesMiceTemozolomideAntineoplastic Agents, AlkylatingDNA Modification MethylasesDNA Repair EnzymesLipid NanoparticlesLipidsLiposomesRNA, Small InterferingTemozolomideTumor Suppressor ProteinsDNA repair enzymelipid nanoparticlepancreatic neuroendocrine tumorsiRNAtemozolomide

Identifiers

PMID41919978
PMCPMC13085844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.